Document is current
Any future updates will be listed below
-
Authors
Manriquez-Roman, Claudia
Siegler, Elizabeth L.
Gleba, Justyna J.
Huynh, Truc N.
DeFranco, Grace E.
Demirer, Aylin Alasonyalilar
Pawlush, Matthew L.
Redig, Michael
Klinge, Skyeler M.
Mai, Long K.
Miller, James L.
Miller, Erin E.
Kimball, Brooke L.
Tapper, Erin E.
Sakemura, R. Leo
Stewart, Carli M.
Can, Ismail
Sirpilla, Olivia L.
Feigin, Jennifer M.
Yun, Kun
Gutierrez-Ruiz, Omar L.
Xia, Hong
Hefazi, Mehrdad
Schick, Kendall J.
Ogbodo, Ekene J.
Olivier, Gloria
Qiu, Yushi
Smallridge, Robert C.
Zubair, Abba
Tun, Han W.
Copland, John A.
Kenderian, Saad S.
-
Funding
Funding for this research was provided by:
Mayo Clinic Center for Regenerative Biotherapeutics
Mayo Clinic Comprehensive Cancer Center
National Institutes of Health
Department of Defense
- License Information
-
More Information
Article History
Received: 1 May 2026
Accepted: 13 July 2026
First Online: 31 July 2026
Declarations
Ethics approval and consent to participate: The use of recombinant DNA in the laboratory was approved by the Mayo Clinic Institutional Biosafety Committee (IBC), IBC number HIP00001516.06. Animal studies were performed according to the Institutional Animal Care and Use Committee (IACUC) at the Mayo Clinic animal facilities (IACUC # A00001767), including adherence to tumor burden guidelines of tumors no greater than 10% of mouse body weight.
Consent for publication: All authors have reviewed and approved the final version of the manuscript for publication.
Competing interests: SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis). SSK and RLS are inventors on patents that are licensed to Humanigen/Taran (through Mayo Clinic). SSK is an inventor on patents that are licensed to MustangBio (through Mayo Clinic). ELS, EET, RLS, OLS, KJS, and SSK are inventors on patents that are licensed to Chymal (through Mayo Clinic). CMR, ELS, TNH, LKM, BLK, RLS, CMS, IC, OLS, JMF, KY, OGR, HX, MHT, JAC and SSK are inventors on patents licensed to Immix (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen/Taran, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen. SSK has participated in advisory meetings with Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, Carisma, and Novartis. SSK has served on the data safety and monitoring board with Humanigen. SSK has served as a consultant for Torque, Calibr, Novartis, Capstan Bio, Carisma Therapeutics, JW Therapeutics, and Humanigen.
